Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis
Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.
Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.
“As a first-in-class, oral, small molecule inhibitor of PARP14, RBN-3143 has the potential to treat a range of inflammatory diseases, including but not limited to atopic dermatitis, asthma and ulcerative colitis. Following the successful completion of the single and multiple ascending dose assessment in healthy subjects to assess safety and pharmacokinetics, we are pleased to be advancing this study into patients with moderate-to-severe atopic dermatitis, the first therapeutic area of focus for the RBN-3143 program,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “As a leading company focused on novel targets in the field of cellular stress response, the initiation of the atopic dermatitis portion of our Phase 1 study marks an important advancement in evaluating NAD+-utilizing enzymes as targets for inflammatory diseases.”
“In preclinical models, RBN-3143 suppresses markers of disease, demonstrating its potential as an oral alternative to biologics in a broad range of inflammatory diseases of the skin, lung and the gastrointestinal system,” said Sudha Parasuraman, M.D., Chief Medical Officer, Ribon Therapeutics. “RBN-3143 has demonstrated a favorable safety and pharmacokinetic profile in healthy subjects and we look forward to its evaluation in patients with moderate-to-severe atopic dermatitis and to demonstrate proof-of mechanism.”
About PARP14
PARP14 is a NAD+-utilizing monoART (mono-ADP-ribosyltransferase) controlling cell signaling and regulating protein function. PARP14 expression is elevated in tissues of various inflammatory diseases, but it is not highly expressed in normal tissues. Elevated PARP14 expression leads to higher levels of first order cytokines, specifically alarmins, and second order cytokines, Th2 and Th17 cytokines, in the inflammatory lesion, and ultimately the increase in disease tissue eosinophils and neutrophils which drive pathology.
About RBN-3143
RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases. This is the second program emerging from the BEACON+ platform to enter clinical development. Selective inhibition of PARP14 leads to a decrease in alarmins and dampening of the IL-17 and IL-4/13 signaling pathways. Ribon has demonstrated efficacy in multiple preclinical models of inflammatory disease. RBN-3143 is currently being evaluated in a Phase 1 clinical study in healthy volunteers and atopic dermatitis patients.
About Ribon Therapeutics
Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon’s portfolio includes two oral, first-in-class clinical programs, RBN-2397 (a PARP7 inhibitor) and RBN-3143 (a PARP14 inhibitor), targeting broad indications in oncology and inflammatory diseases, respectively. The company explores novel areas of biology with the goal of developing effective treatments for patients with limited therapeutic options.
Leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, Ribon is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase), which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit https://ribontx.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005186/en/